[(89)Zr]bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic NF2-related schwannomatosis: a study protocol for a phase II single centre, prospective, feasibility trial.

Douwes JPJ, Tops AL, Dibbets-Schneider P, Verbist BM, Fuentealba Bassaletti CA, Jansen JC, Koetsier KS, van Dam VS, Koot RW, van Velden FHP, Pool M, Vugts D, Schopman JE, Goeman JJ, De Geus-Oei LF, Hensen EF, Gelderblom H

Open source

DOI: 10.1136/bmjopen-2025-114812
Published: 2026 Apr 8
Container: BMJ open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2025-114812,
  title = {[(89)Zr]bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic NF2-related schwannomatosis: a study protocol for a phase II single centre, prospective, feasibility trial.},
  author = {Douwes JPJ and Tops AL and Dibbets-Schneider P and Verbist BM and Fuentealba Bassaletti CA and Jansen JC and Koetsier KS and van Dam VS and Koot RW and van Velden FHP and Pool M and Vugts D and Schopman JE and Goeman JJ and De Geus-Oei LF and Hensen EF and Gelderblom H},
  year = {2026},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2025-114812},
  url = {https://doi.org/10.1136/bmjopen-2025-114812}
}

RIS

TY  - JOUR
TI  - [(89)Zr]bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic NF2-related schwannomatosis: a study protocol for a phase II single centre, prospective, feasibility trial.
AU  - Douwes JPJ
AU  - Tops AL
AU  - Dibbets-Schneider P
AU  - Verbist BM
AU  - Fuentealba Bassaletti CA
AU  - Jansen JC
AU  - Koetsier KS
AU  - van Dam VS
AU  - Koot RW
AU  - van Velden FHP
AU  - Pool M
AU  - Vugts D
AU  - Schopman JE
AU  - Goeman JJ
AU  - De Geus-Oei LF
AU  - Hensen EF
AU  - Gelderblom H
PY  - 2026
JO  - BMJ open
DO  - 10.1136/bmjopen-2025-114812
UR  - https://doi.org/10.1136/bmjopen-2025-114812
ER  -

APA

JPJ, D., AL, T., P, D., BM, V., CA, F. B., JC, J., KS, K., VS, V. D., RW, K., FHP, V. V., M, P., D, V., JE, S., JJ, G., LF, D. G., EF, H., & H, G. (2026). [(89)Zr]bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic NF2-related schwannomatosis: a study protocol for a phase II single centre, prospective, feasibility trial.. BMJ open. https://doi.org/10.1136/bmjopen-2025-114812

Source records

pubmed · retrieved 2026-09-27T00:21:35.322Z